Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553

NEXT STORY
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
PREV STORY
Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an ...

author_avatar
NASDAQ Market News

Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights

YARDLEY, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused ...

author_avatar
NASDAQ Market News

Immunicum AB (publ) Clarifies Information Regarding Directed Issue

Press Release 16 October 2018 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, ...

author_avatar
NASDAQ Market News